Replication stress inhibition synergizes with DNA damaging agents in human cells. Replication stress inhibition synergizes with DNA damaging agents in.

Slides:

Advertisements

Similar presentations

Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin. Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin.

Advertisements

DNA damage foci in irradiated cells.

PARPi combinations against HR-proficient tumors.

Binding of 53BP1 on uncapped telomeres.

Antitumor activity of BAY in patient-derived tumor models.

Activated membrane signaling promotes survival in response to radiation. Activated membrane signaling promotes survival in response to radiation. Radiation.

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

ROS induction and ATR inhibition synergize in inducing multiple myeloma (MM) cell death. ROS induction and ATR inhibition synergize in inducing multiple.

Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. A,

Cell viability assay in NSCLC cell lines in response to gefitinib and Taxol. Cell viability assay in NSCLC cell lines in response to gefitinib and Taxol.

A, IC50 dose–response curves of SYD985, T-DM1, and ADC isotype control in all USC cell lines tested in vitro (i.e., HER2 3+ cell lines, P =

Inhibition of glucagon-induced glycogenolysis in human primary hepatocytes. Inhibition of glucagon-induced glycogenolysis in human primary hepatocytes.

Apoptosis induced by ssHHT in HL60 and its derivative, the HL60/MRP, cells. Apoptosis induced by ssHHT in HL60 and its derivative, the HL60/MRP, cells.

Effects of PS-341 on apoptosis in orthotopic human pancreatic tumors.

GR cells are dependent upon sustained CDC25C signaling as pharmacologic or genetic inhibition of CDC25C induce synthetic lethality. GR cells are dependent.

Effects of PS-341 on human pancreatic cancer cells in vitro.

Antitumor immunity caused by DS-8201a.

T-VISA is robust in ovarian cancer cell lines.

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

PTENP1 sensitizes renal cancer cells to chemotherapy.

A, cytotoxicity induced on HER2 3+ USC (ARK-2), HER2 0/1+ USC (ARK-4), and ARK-2/ARK-4 cocultures with 1 μg/mL of SYD985, T-DM1, and ADC isotype control.

Effects of knockdown of ANRIL on NSCLC cell cycle and apoptosis in vitro. Effects of knockdown of ANRIL on NSCLC cell cycle and apoptosis in vitro. A,

CDDO-Me induces apoptosis independent of Bcl-2 level as well as p53 status in human NSCLC cells. CDDO-Me induces apoptosis independent of Bcl-2 level as.

Simulations to guide drug design strategies for anti–Bcl-2 therapy.

DNA recombination at sites of replication damage in BLM-deficient cells. DNA recombination at sites of replication damage in BLM-deficient cells. A. Nucleotide.

TSA-mediated changes in cell cycle inhibitor proteins.

Radiosensitization by combined Wee1 and PARP inhibition.

CAT displays very high in vivo stability as exemplified by a rat PK study. CAT displays very high in vivo stability as exemplified by a rat.

Inhibition of stress-associated MAPK signaling attenuates SASP expression in CAFs. A, N-CAFs were treated with 100 nmol/L GEM plus DMSO or the above-listed.

Depletion of HDAC2 sensitizes cells to epirubicin-induced apoptosis.

Cisplatin plus PTUPB decreases proliferation and angiogenesis but increases apoptosis as determined by immunohistochemical (IHC) analysis. Cisplatin plus.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

DNA damage-induced RPA foci in asynchronous cells labeled with BUdR.

Kaplan–Meier curves for PFS and OS (for patients treated with anti-PD-1/PD-L1 monotherapy). Kaplan–Meier curves for PFS and OS (for patients treated with.

HNSCC and NSCLC cell lines display differential sensitivities to cixutumumab in the 3D mimic condition. HNSCC and NSCLC cell lines display differential.

Positions of the EGFR exon 20 insertions identified over a 3-year period and comparison with the spectrum of EGFR exon 19 and HER2 insertion mutations.

Src expression in a panel of human TCC cell lines.

LY induces replication stress and depletes the pool of available RPA2 for binding to DNA. HeLa cells were treated with 0.4% DMSO, 100 nmol/L LY

Antitumor effects of celastrol in vitro and in vivo.

Cocultivation of fibroblasts with epithelial cells (EP156T-luc).

Colony formation of K-562 cells after 24 h (upper panel) or 48 h (lower panel) exposure to ErPC3 (20 μm) and ASO-bcr (10 μm), respectively. Colony formation.

Discovered and replicated positive correlation between miR-193b

Effect of miRNA mimic on platinum sensitivity.

Xenograft regrowth studies.

Comparison of the frequency of nucleotide variation in the mtDNA D-loop region between stomach and other tumor cell lines. Comparison of the frequency.

Combination of miR-520d-3p and EphA2 siRNA treatment shows enhanced EphA2 inhibition and antitumor efficiency in vitro. Combination of miR-520d-3p and.

A, P causes G2-M arrest with apoptosis in asynchronous population of PC-3 when exposed to 1.5 and 5 μmol/L P for various time points. A, P

Combined inhibition of Wee1 and PARP causes persistent radiation-induced DNA damage. Combined inhibition of Wee1 and PARP causes persistent radiation-induced.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Effects of EGCG on the anchorage-independent growth of EFT cells.

Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.

CRA inhibits the growth of human tumor xenografts in vivo.

A, expression of p53 downstream mediator p21.

Inhibitions of the proteasome and aggresome pathways by bortezomib and DACi. Unfolded and/or misfolded proteins are targeted by ubiquitin for degradation.

Changes in signal transduction pathway induced by gefitinib.

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

Characterization of DNA-PK and PARP-1 levels and activities in the cell lines studied. Characterization of DNA-PK and PARP-1 levels and activities in the.

High-throughput drug screen (HTDS) reveals ARS1620 and PI3K pathway inhibitors synergies and a heterogeneous pattern of RTK synergies. High-throughput.

Pdcd4 expression inhibits AP-1 transactivation.

Three different endocytoses contribute to ATP internalization.

Cell-cycle regulatory proteins were controlled by O-GlcNAc at FOXO3 S284 through MDM2. Cell-cycle regulatory proteins were controlled by O-GlcNAc at FOXO3.

The effects of AZD1775 and olaparib on DNA damage response signaling.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

Transfection efficiency and PicoGreen cell survival assays.

Blocking αvβ3/galectin-3 binding with GCS-100 selectively kills KRAS-addicted lung cancer cells. Blocking αvβ3/galectin-3 binding with GCS-100 selectively.

Depleting NQO1 expression levels inhibits growth of NSCLC cells in soft agar. Depleting NQO1 expression levels inhibits growth of NSCLC cells in soft agar.

MTOR kinase inhibition–induced reactivation of AKT substrates is HER2 and PI3K dependent. mTOR kinase inhibition–induced reactivation of AKT substrates.

Identification and characterization of activated integrin pathway module by signal transduction representation (A) and unsupervised hierarchical clustering.

Loss of NQO1 expression inhibits invasion of NSCLC

WEE1 inhibition followed by TRAIL treatment results in apoptotic cell death in MB231 cells. WEE1 inhibition followed by TRAIL treatment results in apoptotic.

Presentation transcript:

Replication stress inhibition synergizes with DNA damaging agents in human cells. Replication stress inhibition synergizes with DNA damaging agents in human cells. A, Synergy scores of the combination matrix of cisplatin and the ATR inhibitor VE-822 tested in a panel of 6 human SCLC cell lines. B, Synergy score of the combination of cisplatin and VE-822 tested on primary human fibroblasts. All synergy scores were calculated using the MAC Synergy II algorithm using data from three independent experiments. C, Comparison of the synergy volumes of a panel of 6 SCLC and 6 NSCLC cell lines. Synergy volumes were obtained from the experiments represented in Fig. 3A and Supplementary Fig. S2C. Statistical significance was calculated using a Student t test. Remco Nagel et al. Mol Cancer Ther 2019;18:762-770 ©2019 by American Association for Cancer Research